Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prognostic value of preoperative ctDNA and pathological venous invasion for recurrence in EGFR-mutated non-small cell lung cancer.

Lung cancer (Amsterdam, Netherlands) - 1 Mar 2026

Murase Yuya, Koba Hayato, Kimura Hideharu, Matsumoto Isao, Ueda Tsukasa, Nomura Shunichi, Arai Sachiko, Terada Nanao, Yifeng Liu, Nanjo Shigeki, Tambo Yuichi, Kobayashi Takafumi, Watanabe Satoshi, Yamamura Kenta, Ohkura Noriyuki, Abo Miki, Nomura Akihiro, Yano Seiji

Abstract excerpt

INTRODUCTION: Curative surgery followed by adjuvant osimertinib according to pathological stage (pStage) is standard for resectable epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC). Nevertheless, recurrence remains a concern even in Stage IA, for which adjuvant osimertinib is not indicated. We evaluated the utility of circulating tumor DNA (ctDNA) to predict recurrence in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Circulating Tumor DNA

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Indoles

Share to Neoplasm Invasiveness

Share to Neoplasm Recurrence, Local

Share to Neoplasm Staging

Share to Pyrimidines

Source

Identifiers

PMID: 41546895
DOI: 10.1016/j.lungcan.2025.108818

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prognostic value of preoperative ctDNA and pathological venous invasion for recurrence in EGFR-mutated non-small cell lung cancer.PMID 41546895Read ↗

Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC.Semantic proximity Read ↗

Clinical, Pathologic, and Molecular Prognostic Factors in Patients with Early-Stage EGFR-Mutant NSCLC.Semantic proximity Read ↗

Prognostic potential of circulating tumor DNA detection at different time periods in resectable non-small cell lung cancer: Evidence from a meta-analysis.Semantic proximity Read ↗

ctDNA for the Evaluation and Management of EGFR-Mutant Non-Small Cell Lung CancerSemantic proximity Read ↗

EGFR mutation status, treatment patterns, and outcomes in resectable early-stage non-small cell lung cancer prior to adjuvant EGFR-TKI approval: An international real-world study.Semantic proximity Read ↗

Longitudinal Monitoring of Circulating Tumor DNA From Plasma in Patients With Curative Resected Stages I to IIIA EGFR-Mutant Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Perioperative ctDNA-Based Molecular Residual Disease Detection for Non-Small Cell Lung Cancer: A Prospective Multicenter Cohort Study (LUNGCA-1).Semantic proximity Read ↗

Early assessment of circulating tumor DNA after curative-intent resection predicts tumor recurrence in early-stage and locally advanced non-small-cell lung cancer.Semantic proximity Read ↗

Real-World Utilization and Performance of Circulating Tumor DNA Monitoring to Predict Recurrence in Solid TumorsSemantic proximity Read ↗

Clinical correlations with EGFR circulating tumor DNA testing in all-stage lung adenocarcinoma.Semantic proximity Read ↗

Circulating tumor DNA and radiological tumor volume identify patients at risk for relapse with resected, early-stage non-small-cell lung cancer.Semantic proximity Read ↗

Spatiotemporal genomic analysis reveals distinct molecular features in recurrent stage I non-small cell lung cancers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.